OVID

Ovid Therapeutics Inc

• TipRanks·3d ago

  Ovid Therapeutics: Advancing Seizure Pipeline and Neuropsychiatric Programs Support Buy Rating and Unchanged $4 Price Target

• TipRanks·05/14 14:49

  Ovid Therapeutics price target raised to $7 from $5 at Roth Capital

• TipRanks·05/14 10:40

  Analysts’ Top Healthcare Picks: GRI Bio (GRI), Ovid Therapeutics (OVID)

• TipRanks·05/13 13:39

  B. Riley Securities Keeps Their Buy Rating on Ovid Therapeutics (OVID)

• TipRanks·05/13 12:40

  Analysts Offer Insights on Healthcare Companies: Legend Biotech (LEGN), Ovid Therapeutics (OVID) and Arvinas Holding Company (ARVN)

• TipRanks·05/13 10:30

  Analysts Are Bullish on Top Healthcare Stocks: Kura Oncology (KURA), Savara (SVRA)

• TipRanks·05/12 20:10

  Analysts Are Bullish on Top Healthcare Stocks: Ovid Therapeutics (OVID), Imunon (IMNN)

• TipRanks·05/12 12:02

  Ovid Therapeutics reports Q1 EPS (12c), consensus (11c)

• Reuters·05/12 11:11

  Ovid Therapeutics Q1 net loss widens as R&D spending rises

• PUBT·05/12 11:10

  Ovid Therapeutics releases corporate presentation on neural hyperexcitability drug pipeline

• Dow Jones·05/12 11:08

  *Ovid Therapeutics 1Q Research and Development Expenses $11.2M >OVID

• PUBT·05/12 11:06

  Ovid Therapeutics Q1 FY26 net loss widens to $17 million; R&D expenses climb to $11.2 million

• Seeking Alpha·05/12 11:04

  Ovid Therapeutics GAAP EPS of -$0.12 in-line

• Dow Jones·05/12 11:00

  Press Release: Ovid Therapeutics Reports Business -2-

• Dow Jones·05/12 11:00

  *Ovid Therapeutics 1Q Loss/Shr 12c >OVID